

Bulletin #828

February 9, 2012

## NBPDP FORMULARY UPDATE

### OXYCONTIN<sup>®</sup> NO LONGER AVAILABLE

This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective February 9, 2012

**Included in this bulletin:**

- **Notice of discontinuation of OxyContin<sup>®</sup>**
- **Options for patients currently receiving OxyContin<sup>®</sup>**
- **Drugs (including OxyNEO<sup>™</sup>) Reviewed and Not Listed**

If you have any questions, please contact our office at 1-800-332-3691.

To unsubscribe from the NBPDP emailed announcements, please send a message to [info@nbpdp-pmonb.ca](mailto:info@nbpdp-pmonb.ca).  
The Updates are available on the NBPDP webpage: <http://www.gnb.ca/0212/BenefitUpdates-e.asp>

## DISCONTINUATION OF OXYCONTIN<sup>®</sup>

Purdue Pharma has announced that OxyContin<sup>®</sup> will be discontinued and distribution will cease no later than February 29, 2012. The following DINs are affected:

OxyContin <sup>®</sup>	Strength	DIN	Strength	DIN
	5 mg tablet	02258129	30 mg tablet	02323206
	10 mg tablet	02202441	40 mg tablet	02202476
	15 mg tablet	02323192	60 mg tablet	02323214
	20 mg tablet	02202468	80 mg tablet	02202484

Therefore, as of February 15, 2012 no new special authorization requests for OxyContin<sup>®</sup> will be considered by the NBPDP. Please note that OxyNEO<sup>™</sup>, a new formulation of long-acting oxycodone, has been reviewed and is not approved for listing on the NBPDP Formulary.

## OPTIONS FOR PATIENTS CURRENTLY RECEIVING OXYCONTIN<sup>®</sup>

As of March 1, 2012, NBPDP beneficiaries currently receiving OxyContin<sup>®</sup> (who have received coverage in the 3 months prior to March 1, 2012) will be eligible to receive coverage of OxyNEO<sup>™</sup>. NBPDP beneficiaries changing to OxyNEO<sup>™</sup> will require a new prescription if their physician deems it appropriate, but will **not** need a new special authorization request as their approved coverage for OxyContin<sup>®</sup> will apply to OxyNEO<sup>™</sup>. Other than in the circumstance stated here, OxyNEO<sup>™</sup> will **not** be considered under the special authorization process.

The NBPDP Formulary currently lists many alternative short- and long-acting opioid medications such as codeine, morphine, hydromorphone, and fentanyl patches, as well as, non-narcotic agents used in the treatment of pain. The NBPDP Formulary is available at: [www.gnb.ca/0051/0212/index-e.asp](http://www.gnb.ca/0051/0212/index-e.asp) or call the NBPDP inquiry line at 1-800-332-3691 for more information on listed products.

## DRUGS REVIEWED AND NOT LISTED

The review of the following products found they did not offer a significant therapeutic and/or cost advantage over existing therapies. Requests for special authorization will not be considered.

<b>Oxycodone</b>	( <i>OxyNEO<sup>™</sup></i> )	10, 15, 20, 30, 40, 60, 80 mg controlled-release tablets
<b>Cyclosporine</b> – moderate to moderately severe dry eye disease	( <i>Restasis<sup>®</sup></i> )	0.05% ophthalmic emulsion
<b>Maraviroc</b> – for HIV-1 treatment-naïve, adult patients	( <i>Celsentri<sup>®</sup></i> )	150 mg, 300 mg tablets
<b>Roflumilast</b> – chronic obstructive pulmonary disease	( <i>Daxas<sup>®</sup></i> )	500 µg tablets